Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Revance Therapeutics, Inc. (RVNC)

Pharmaceutical Preparations

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

1222 DEMONBREUN STREET, SUITE 2000
NASHVILLE, TN

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/06/2014

Market Cap

688,115,505

Shares Outstanding

87,810,000

Weighted SO

87,813,480

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

DMAC --.--%

AKRO --.--%

NUVL --.--%

IMCR --.--%

VTYX --.--%

ACLX --.--%

ETNB --.--%

PLRX --.--%

APLS --.--%

Beta

0.9790

Last Div

0.0000

Range

2.3-19.01

Chg

0.0150

Avg Vol

3277920

Mkt Cap

688115505

Exch

NASDAQ

Country

US

Phone

615 724 7755

DCF Diff

9.3913

DCF

23.7387

Div Yield

0.0000

P/S

2.8213

EV Multiple

-6.5103

P/FV

-5.2881

Div Yield %

0.0000

P/E

-2.3863

PEG

-0.1093

Payout

0.0000

Current Ratio

3.7399

Quick Ratio

3.0106

Cash Ratio

0.8729

DSO

54.0062

DIO

335.6417

Op Cycle

389.6480

DPO

24.5021

CCC

365.1459

Gross Margin

0.6955

Op Margin

-1.1195

Pretax Margin

-1.1626

Net Margin

-1.1788

Eff Tax Rate

-0.0187

ROA

-0.5810

ROE

2.3652

ROCE

-0.6806

NI/EBT

1.0139

EBT/EBIT

1.0386

EBIT/Rev

-1.1195

Debt Ratio

0.9190

D/E

-3.5047

LT Debt/Cap

1.4423

Total Debt/Cap

1.3992

Int Coverage

-27.1193

CF/Debt

-0.4415

Equity Multi

-3.8138

Rec Turnover

6.7585

Pay Turnover

14.8967

Inv Turnover

1.0875

FA Turnover

2.6336

Asset Turnover

0.4929

OCF/Share

-1.9328

FCF/Share

-2.0143

Cash/Share

2.2386

OCF/Sales

-0.8231

FCF/OCF

1.0422

CF Coverage

-0.4415

ST Coverage

-6.3512

CapEx Coverage

-23.7193

Div&CapEx Cov

-23.7193

P/BV

-5.2881

P/B

-5.2881

P/S

2.8213

P/E

-2.3863

P/FCF

-3.2889

P/OCF

-3.4173

P/CF

-3.4173

PEG

-0.1093

P/S

2.8213

EV Multiple

-6.5103

P/FV

-5.2881

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 23, 02:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge and Revance and Encourages Investors to Contact the Firm Benzinga Jan 08, 01:24 RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire Inc. Nov 09, 15:30 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders Benzinga Oct 16, 03:09 INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors Benzinga Nov 22, 12:00 What 10 Analyst Ratings Have To Say About Revance Therapeutics Benzinga Nov 06, 14:00 The Latest Analyst Ratings for Revance Therapeutics

Revenue Product Segmentation